Executive Team

Patrick Bennett

Patrick Bennett

Chief Executive Officer

Patrick Bennett

Patrick Bennett

Chief Executive Officer

Patrick has over 35 years’ experience in pharmaceutical analysis and laboratory management. From 1987 to 1993, he was a research scientist with the Bristol-Myers Company/Bristol-Myers Squibb. In 1993, he was the Lab Director at Advion (now IQVIA) in Ithaca, NY. In 1998, Patrick joined Tandem Labs (now LabCorp Drug Development) where he held the positions of Sr. Laboratory Director, General Manager and Vice President in a variety of roles at several of the Tandem Lab’s sites. His focus on method development processes and innovation resulted in the bridging of good science, speed, and customer focus. In 2010, Patrick joined Thermo Fisher Scientific as Strategic Marketing Director for Pharma and introduced the Q Exactive and Fusion mass spectrometers. Between 2014 and 2022, Patrick was Vice President of Strategy and Development at PPD Laboratories. He started the PPD biomarker lab, organized the Cell and Gene Therapy team and was responsible for the creation of PPD Labs in Suzhou, China. He is currently CEO of Alliance Pharma, Inc.

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.

Alex Abramov

Alex Abramov

Chief Financial Officer (CFO)

Alex Abramov

Alex Abramov

Chief Financial Officer (CFO)

Vito Saccente

Vito Saccente

Chief Commercial Officer (CCO)

Vito Saccente

Vito Saccente

Chief Commercial Officer (CCO)

Vito Saccente was appointed Chief Commercial Officer in July 2022 and brings over 25+ years of Sales Leadership experience in the Life Science, CRO industry including all aspects of nonclinical, clinical and CMC product development of vaccines, small molecules and large molecules.

Prior to joining Alliance Pharma, Vito was the Vice President of Sales, Vaccines and Biosciences for Q2 Solutions where he oversaw the commercial strategy and growth for vaccine, bioanalytical and ADME testing services. He also had active contributions to the corporate strategy for merger and acquisitions in his business unit.

Outside of work Vito enjoys time with family, golf and staying active.

Vito holds a Bachelor of Science degree, Business Administration from Monmouth College (now University) and has successfully completed management development programs from Harvard University and University of Southern California.

Jing Tu

Jing Tu

Head of Corporate Development and Strategy

Jing Tu

Jing Tu

Head of Corporate Development and Strategy

Jing Tu is Head of Corporate Development and Strategy at Alliance Pharma (PA, USA). Jing has been working in the CRO and pharmaceutical industry since 2011. She started her career with Frontage Laboratories (PA, USA) in its biologics ligand binding services lab. As a Frontage scientist, she was then selected by Janssen R&D (formerly Centocor) to work within their ligand-binding laboratories in Spring House (PA, USA). In 2015, Jing joined PPD Laboratories’ (VA, USA) biomarker lab and started its biomarker ligand binding assay group. In 2018, Jing Joined the AbbVie (MA, USA) DMPK department and led its pre-clinical large molecule bioanalysis support. 

Jing has an M.B.A degree from Yale University (CT, USA) and graduated as the Class Marshall. She also has a medical degree from Norman Bethune School of Medicine Jilin University (Changchun, China).

Jing was a member of the Global CRO Council (GCC) from 2016 to 2018. She is also a current member of the organizing committee for Applied Pharmaceutical Analysis (APA), Bioanalysis Zoom Leader, and Expert Columnist. In 2018, she was named the winner of the Bioanalysis Rising Star Award.

Zhiyang Zhao, Ph.D.

Zhiyang Zhao, Ph.D.

Chief Scientific Officer & EVP Scientific Partnership

Zhiyang Zhao, Ph.D.

Zhiyang Zhao, Ph.D.

Chief Scientific Officer & EVP Scientific Partnership

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Alliance Pharma. Dr. Zhao has over 25 years of pharmaceutical industry experience with special focus on metabolic and pharmacokinetic properties of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Alliance Pharma, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.

Dr. Zhao’s extensive experience spans the entire drug discovery and development process (discovery, development, and in-/out-licensing) in oncology, metabolic, antiviral, CNS, and inflammatory diseases. Dr. Zhao’s contributions and accomplishments of integrating in vitro and in vivo ADMET (absorption, distribution, metabolism, excretion, and toxicity) information to optimize drug candidate properties are documented in over 50 peer‑reviewed scientific publications and patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology.

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and disposition. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.


Scientific Team

Jason Wang

Jason (Hao) Wang

Site President, Australia

Yong Lin

Yong Lin

Director, Biopharmaceutical Services

Aihua Liu, PhD.

Aihua Liu, Ph.D.

Director, Bioanalysis